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Mutation Spectrum in the 
CACNA1A Gene in 49 Patients with 
Episodic Ataxia
Cèlia Sintas1,2,3, Oriel Carreño1,2, Noèlia Fernàndez-Castillo1,2,3,4, Roser Corominas1,2,5,6,7, 
Marta Vila-Pueyo5, Claudio Toma  1,2,3,8,9, Ester Cuenca-León5,10,11, Isabel Barroeta12, Carles 
Roig12,13, Víctor Volpini14, Alfons Macaya5 & Bru Cormand  1,2,3,4
Episodic ataxia is an autosomal dominant ion channel disorder characterized by episodes of imbalance 
and incoordination. The disease is genetically heterogeneous and is classified as episodic ataxia type 2 
(EA2) when it is caused by a mutation in the CACNA1A gene, encoding the α1A subunit of the P/Q-type 
voltage-gated calcium channel Cav2.1. The vast majority of EA2 disease-causing variants are loss-of-
function (LoF) point changes leading to decreased channel currents. CACNA1A exonic deletions have 
also been reported in EA2 using quantitative approaches. We performed a mutational screening of 
the CACNA1A gene, including the promoter and 3′UTR regions, in 49 unrelated patients diagnosed 
with episodic ataxia. When pathogenic variants were not found by sequencing, we performed a copy 
number variant (CNV) analysis to screen for duplications or deletions. Overall, sequencing screening 
allowed identification of six different point variants (three nonsense and three missense changes) and 
two coding indels, one of them found in two unrelated patients. Additionally, CNV analysis identified 
a deletion in a patient spanning exon 35 as a result of a recombination event between flanking intronic 
Alu sequences. This study allowed identification of potentially pathogenic alterations in our sample, five 
of them novel, which cover 20% of the patients (10/49). Our data suggest that most of these variants are 
disease-causing, although functional studies are required.
Episodic ataxia type 2 (EA2, MIM #108500) is a rare autosomal dominant ion channel disorder caused by muta-
tions in the CACNA1A gene and characterized by episodes of midline cerebellar disturbance manifesting as 
ataxia, imbalance, vomiting, oscillopsia1 and interictal nystagmus; progressive ataxia can eventually develop2. 
EA2 has a wide phenotypic spectrum which includes paroxysmal neurological features other than ataxia. Around 
50% of patients also experience migraine, and 80% suffer from rotational vertigo during the attacks3. Ataxia 
episodes last from hours to 2–3 days and are usually triggered by emotional stress, physical exercise, alcohol 
or caffeine. Onset usually occurs during the second decade of life, although later onsets have been reported3, 4. 
Acetazolamide administration can stop or diminish the frequency and severity of the attacks5.
CACNA1A encodes the pore-forming α1 subunit of the neuronal voltage-gated P/Q-type calcium chan-
nel (Cav2.1), which is widely expressed in the central nervous system (CNS), especially in Purkinje cells and 
1Departament de Genètica, Microbiologia i Estadística, Facultat de Biologia, Universitat de Barcelona, Barcelona, 
Catalonia, Spain. 2Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain. 
3Institut de Biomedicina de la Universitat de Barcelona (IBUB), Barcelona, Catalonia, Spain. 4Institut de Recerca 
Sant Joan de Déu (IR-SJD), Esplugues, Catalonia, Spain. 5Pediatric Neurology Research Group, Vall d’Hebron 
Research Institute, Universitat Autònoma de Barcelona, Barcelona, Catalonia, Spain. 6Department of Health and 
Experimental Sciences, Universitat Pompeu Fabra, Barcelona, Catalonia, Spain. 7Hospital del Mar Research Institute 
(IMIM), Barcelona, Catalonia, Spain. 8Neuroscience Research Australia, Sydney, New South Wales, Australia. 
9School of Medical Sciences, University of New South Wales, Sydney, New South Wales, Australia. 10Psychiatric 
and Neurodevelopmental Genetics Unit (PNGU), Massachusetts General Hospital, Boston, Massachusetts, United 
States of America. 11Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, 
United States of America. 12Department of Neurology, Hospital de la Sta, Creu i St Pau, Barcelona, Catalonia, Spain. 
13Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Catalonia, Spain. 14Centre de Diagnòstic 
Genètic-Molecular, Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), l’Hospitalet de Llobregat, Barcelona, 
Catalonia, Spain. Cèlia Sintas and Oriel Carreño contributed equally to this work. Correspondence and requests for 
materials should be addressed to B.C. (email: bcormand@ub.edu)
Received: 27 October 2015
Accepted: 13 April 2017
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 7: 2514  | DOI:10.1038/s41598-017-02554-x
granule cells of the cerebellum. The Cav2.1 channel is responsible for the coupling of calcium influx to vesicu-
lar exocytosis, mediating neurotransmission6. Since the first CACNA1A disease-causing variants were described 
in EA27, over 80 EA2 alterations have been reported in the gene3. Several other neurological disorders are 
caused by pathogenic variants in CACNA1A, including familial hemiplegic migraine (FHM1, MIM #301011) 
and spinocerebellar ataxia type 6 (SCA6, MIM #183086), and the gene has also been related to other hemi-
plegic migraine (HM)-associated phenotypes like alternating hemiplegia of childhood8, acute striatal necrosis9, 
hemiplegia-hemiconvulsion-epilepsy10 or recurrent ischemic stroke11.
The vast majority of EA2-causing variants in the CACNA1A gene are predicted to cause loss of function of 
the channel, since nonsense, splicing and indel variants have been extensively reported. Furthermore, missense 
variants leading to decreased channel currents have been described3, 4, 12, 13 and over the past years deletions 
in CACNA1A have been reported in EA2 patients using quantitative approaches, such as Multiplex Ligation 
dependent Probe Amplification (MLPA)14, 15 or Quantitative Multiplex PCR of Short fluorescent Fragments 
(QMPSF)16. Functional studies have been carried out to investigate the pathogenic mechanism of EA2 mutations 
by expressing Cav2.1 channels carrying either missense or truncating CACNA1A changes in mammalian cells17, 18  
and Xenopus oocytes19. Two main hypotheses, negative dominance and haploinsufficiency, have been tested.
In this study we aimed to perform an extensive mutation analysis of the CACNA1A gene in 49 unrelated 
patients with episodic ataxia by means of sequencing and CNV analyses to identify both disease-causing point 
variants and structural variants.
Results
Patients. Ten out of 49 patients were found to harbour potentially pathogenic heterozygous CACNA1A vari-
ants (Table 1). Their clinical signs were prototypical for episodic ataxia. However, since most patients were adults 
when interviewed, complete information regarding their clinical presentation and the periods with higher attack 
frequencies was difficult to retrieve. Acetazolamide was generally effective in preventing the spells. Brain MRI 
documented vermian cerebellar atrophy in just one of the ten cases with molecular diagnosis.
Patient
Age of 
onset 
(years)
Frequency of 
the episodes 
(per month) Duration Trigger(s) MRI Other features
Variant
Restriction 
enzyme
PhyloPc/
PhastConsd 
scores
SIFT 
scoree
PolyPhen- 
2 scoref ReferencecDNAa Exon Proteinb Domain
EP-004 infancy NA NA NA NA
ACZ responsive, 
MO, learning 
disability, motor 
clumsiness
c.749delG 5 p.G250Efs*60 DI, S5-S6  loop
+TaqI 
(mismatch) 5.84/1 — — —
432B 6 >1 15′-3 h stress, fatigue normal ACZ responsive c.G959A 6 p.W320*
DI, S5-S6  
loop +AccI 5.78/1 — — —
A03_44 NA NA NA NA NA FHM, interictal ataxia, nystagmus c.C1502T 11 p.T501M
g DII, S1 +FatI 4.32/1 Damaging (0.00)
Probably 
damaging 
(1.00)
24
A98_279 58 ∼30 30′-1 h NA normal episodic hand dystonia c.G1913A 14 p.G638D
DII, S5-S6  
loop −AciI 5.63/1
Damaging 
(0.03)
Probably 
damaging 
(1.00)
4
7A806 5 4 NA NA NA MO c.2042-43delAG 16 p.Q681Rfs*100
DII, S5-S6  
loop -DdeI — — — 21–24
474 8 1–4 3–6 h NA
deep WM 
hyperinte-
nsities
worsen on CBZ 
and PHT, ACZ 
responsive
c.5253-
2259_5403+ 
1135del
35 p.S1753Cfs*2 DIV, S5-S6 loop — — — — —
335a <1 NA 48 h NA normal migraine, visual aura c.T5547A 37 p.Y1849*
Cytoplasmic 
tail −PsiI 4.33/1 — — —
340 4 NA NA
exercise, 
fatigue, 
emotional 
stress
temporal 
arachnoidal 
cyst
congenital squint, 
nystagmus, ACZ 
responsive
c.C5569T 37 p.R1857* Cytoplasmic tail
+BspHI 
(mismatch) 3.33/1 — — 20
389A 2 8–12
6–8 h 
upon 
sleep
stress, 
exercise, 
coffee, 
tea
mild 
cerebellar 
atrophy
improves on 
ACZ, MO, 
interictal ataxia, 
nystagmus
c.C5569T 37 p.R1857* Cytoplasmic tail
+BspHI 
(mismatch) 3.33/1 — — 20
349A 1.5 1–2 30′ stress normal nystagmus c.C6665T 46 p.P2222Lg Cytoplasmic tail −FauI 2.83/1
Tolerated 
(1.00)
Benign 
(0.06) —
Table 1. Clinical information and results from the CACNA1A mutational screening in episodic ataxia patients 
with identified variants. MRI: Magnetic Resonance Imaging; NA: not available; ACZ: acetazolamide; MO: 
migraine without aura; FHM: Familial Hemiplegic Migraine; WM: white matter; CBZ: carbamazepine,; PHT: 
phenytoin; D: domain; S: segment. aReference sequence for cDNA nomenclature: NM_001127221 (nucleotide 
c.279A corresponding to the initiation codon, ATG). bRererence sequence for protein nomenclature: 
NP_001120693. cPhyloP score: Positive scores indicate sites that are predicted to be conserved, whereas negative 
scores indicate sites predicted to be fast-evolving. dPhastCons score: It ranges from 0 (non conserved amino 
acid positions) to 1 (highly conserved amino acid positions). eSIFT score: It ranges from 0 to 1. The amino acid 
substitution is predicted as damaging if the score is <=0.05, and tolerated if the score is >0.05. fPolyPhen-2 
score: It ranges from 0 to 1. The aminoacid substitution is predicted as probably damaging if the score is >0.85, 
possibly damaging (score is between 0.15 and 0.85) or benign (score < 0.15). gVariants p.T501M and p.P2222L 
have the rs codes rs121908240 and rs778551911, respectively.
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Sequencing analysis of CACNA1A. Sanger-sequence analysis of the CACNA1A gene in a cohort of 49 
Spanish individuals diagnosed with episodic ataxia allowed the identification of eight heterozygous variants in 
nine patients (Figs 1 and 2). These included three missense changes, three nonsense variants leading to prema-
ture stop codons (one of them found in two unrelated patients) and two indels causing frame shift (Table 1). All 
variants were confirmed by restriction analysis (Table 1). Four of them are novel and four have been reported 
previously. None of the variants were present in a screening of 200 Spanish control individuals and all but two 
were absent from two different exome databases, one specific for the Spanish population (http://csvs.babelom-
ics.org), including 576 subjects, and the ExAC resource (http://exac.broadinstitute.org) that includes more than 
60,000 individuals. The p.T501M variant was found once in ExAC and p.P2222L was detected in four subjects in 
the same database, whereas the rest of the changes were not present in either dataset. In the nine families where 
a rare CACNA1A variant was identified, seven relatives were also screened for the particular change identified 
in the index case (Fig. 2). These relatives, five with episodic ataxia, one with migraine with aura and one healthy 
subject, belong to four of the families. The six relatives with a paroxystic phenotype bear the same mutation as the 
index case, whereas the healthy individual is not a carrier. In all four pedigrees the variant was transmitted, so no 
de novo changes were revealed by our analyses.
Two of the nonsense variants, p.W320* and p.Y1849*, are described here for the first time. The first one is 
located in the extracellular loop between S5 and S6 from domain I, maintaining only the N-terminus and part of 
the first domain of the protein (Fig. 1). Variant p.Y1849*, in contrast, leads to the truncation of the cytoplasmic 
tail, leaving out of the subunit the calcium binding domain (Fig. 1). Two other patients in our series carried the 
p.R1857* change, reported previously by other authors20.
We identified two coding indels leading to frame shifts and predicting truncated proteins. The novel genetic 
variant c.749delG (p.G250fs*60) is located in the S5-S6 extracellular loop from domain I, the same domain where 
the p.W320* change is located. The second one, c.2042-43delAG (p.Q681Rfs*100) produces a frame shift in 
domain II, also in the extracellular loop S5-S6, with a premature stop codon 100 codons downstream. This variant 
had been described in previous works21–24.
Finally, three missense variants were identified. Two variants had already been reported by our group, but they 
were added to the present study to provide a complete view of our episodic ataxia series: Patient A98_279 carries 
variation p.G638D4 and patient A03_44, diagnosed with both episodic ataxia and FHM carries the p.T501M 
change25. Both reports were accompanied by functional assays. The third variation, p.P2222L, described here for 
the first time, is located in a poly-proline region in the cytoplasmic tail of the protein.
CNV analysis of CACNA1A. The study of potential structural variants in the CACNA1A gene by MLPA 
allowed the identification of a deletion of the entire exon 35 (Fig. 3) in patient 474, which was confirmed by 
QMPSF.
In order to map the deletion breakpoint, a genomic region covering exons 34 to 36 was PCR-amplified and 
sequenced. A recombination occurred between two identical fragments located within Alu sequences in introns 
34 (AluY) and 35 (AluSz), proximal and distal from exon 35 (Fig. 3), resulting in a 3.5-kb deletion. This novel 
deletion disrupts the coding frame from amino acid position 1,752 and is predicted to lead to a premature trun-
cation only one residue downstream (p.S1752Cfs*2) in the extracellular S5-S6 loop of domain IV.
Figure 1. CACNA1A gene and protein structure with the identified pathogenic variants. CACNA1A gene 
structure (top figure), with boxes indicating exons. Protein structure of the Cav2.1α1A subunit (bottom 
figure). The genetic variants reported in this work are indicated by dots. Cyt: cytoplasm; M: cytoplasmic 
membrane; ES: extracellular space; S: Segment. Reference sequence for cDNA nomenclature: NM_001127221 
(nucleotide c.279A corresponding to the initiation codon, ATG). Rererence sequence for protein nomenclature: 
NP_001120693.
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Nonsense mediated mRNA decay (NMD) assay. An NMD assay was performed from skin fibroblasts 
of patient 432B, bearing a heterozygous p.W320* stop variant. Sanger sequencing and RFLP analysis were per-
formed and the mutated allele was shown to be present both in cells treated with cycloheximide (an inhibitor of 
mRNA decay) and those untreated. Gel quantification showed that the transcript produced from the mutated 
allele accounts for 55% of the total amount of product), indicating that this process does not trigger degradation 
of the mRNA encoding the truncated protein (Supplementary Fig. S1).
Discussion
Here we report an exhaustive screening of the CACNA1A gene in a large sample of patients with episodic ataxia, 
which was addressed through Sanger sequencing and CNV analyses. We identified nine different potentially 
pathogenic genetic variants in 10 of the 49 patients studied, five of which are novel (Table 1). This represents 
resolution of 20.4% of our patients sample, a percentage that is similar to others reported elsewhere1, 26. All these 
variants map to exons that are present in the main CACNA1A isoform (NM_001127221), which is expressed in 
brain, with highest expression in the cerebellar cortex, according to the public transcriptomic datasets Allen Brain 
Atlas (http://human.brain-map.org) and Human Brain Transcriptome (http://hbatlas.org/pages/hbtd). Although 
most of the previously reported changes in episodic ataxia type 2 (EA2) are point variations, deletions encom-
passing one or more CACNA1A exons have also been described14–16, 27. For this reason, in addition to sequencing 
exons, splice sites, branch points and the promoter region of the gene, we used two complementary quantitative 
approaches, MLPA and QMPSF, to extend the mutational screening of deletions and duplications within the 
gene. MLPA and QMPSF allowed inspection of 40 out of 48 CACNA1A exons (Supplementary Fig. S2). Thus, an 
exhaustive genetic diagnostic protocol consisting of two sequential approaches offered a wider and more compre-
hensive view of the genetic background of EA2.
We identified a total of three nonsense and three missense variants, two indels (one of them found in two 
patients) and a deletion encompassing exon 35 of the gene. From these, six were predicted to truncate the protein, 
either by introducing a stop codon (p.W320*, p.Y1849* and p.R1857*) or by causing a frame shift (p.G250Efs*60, 
p.Q681Rfs*100 and p.S1752Cfs*2). Disrupting variants that result in a loss of function of the Cav2.1 calcium 
channel are the most commonly reported changes in EA2 patients. Functional analyses of the truncated 
CACNA1A subunit have showed diminished or null activity of the channel for EA2 mutations18. Thus, although 
truncating mutations have usually shown to cause a loss of function of the mutated subunit, the underlying 
Figure 2. Pedigrees from individuals with identified changes. The code on top of every pedigree corresponds 
to the proband individual, indicated by a black arrow. Affected individuals are denoted by solid symbols; 
episodic ataxia is indicated in black and other phenotypes in gray; squares indicate males and circles indicate 
females. Clinical characteristics are indicated below each individual (EA2: episodic ataxia type 2; FHM: familial 
hemiplegic migraine; MO: migraine without aura; MA: migraine with aura). Gene variant carrier status is 
indicated below individuals. A complete screening of the CACNA1A gene was performed by Sanger sequencing 
and CNV analysis only in the probands (indicated by an arrow), whereas in the other family members where 
the genotype is indicated, only the variant identified in the proband was tested. In those individuals where the 
genotype is not shown, DNA was not available for analysis.
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pathophysiological mechanism that causes the EA2 phenotype remains still unclear. Two hypotheses have been 
proposed: haploinsufficiency, supported by the finding of nonsense mediated RNA decay (NMD)15, 28, and a 
dominant negative effect of the mutated subunit. The latter is more generally accepted as the major mechanism 
on the basis of functional studies that support an altered interaction between the WT and the mutated allele that 
would retain the complex in the endoplasmic reticulum, affecting protein trafficking and activating the proteas-
ome response17, 29, 30. The dominant negative effect of the interaction may require the presence of the N-terminus 
of the protein in the mutant form, leading to a suppression of the Cav2.1 channel expression due to the interaction 
between truncated and full-length subunits18. All six truncating changes reported here are located beyond the 
N-terminus of the channel and so are candidates to undergo dominant negative effects.
In our study, since skin fibroblasts from patient 432B (p.W320*) were available, the hypothesis of haploinsuf-
ficiency caused by a possible degradation of the mutated mRNA by NMD could be tested. No mRNA degradation 
was observed for this particular genetic variant in these cells (see Supplementary Fig. S1), although this result may 
not reflect what actually occurs in brain. NMD could not be tested in the rest of the patients from our collection, 
as biological samples were not accessible for analysis.
Figure 3. CNV studies in the CACNA1A gene of patient 474. (a) Results from the MLPA analysis performed 
with Coffalyser. The deleted exon 35 is indicated with an arrow. C: control probe. (b) Deletion breakpoint 
mapping. Sequence chromatogram corresponding to the homologous fragment from AluY and AluSz 
sequences. The identical shared sequence by the 5′ and 3′ Alu elements located in introns 34 and 35 that 
mediated the recombination is framed. Location of fragments taken from UCSC Genome Browser on Human 
Feb. 2009 Assembly (GRCh37/hg19).
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Three heterozygous missense variants (p.T501M, p.G638D and p.P2222L) were identified in three patients. 
The effect of missense variants are not easy to predict functionally. Two of the variants that we describe in this 
study, p.G638D and p.T501M, had been reported in previous works from our group, where functional analyses 
were performed4, 25. Variant p.G638D showed a loss of function of the channel, in agreement with the most 
commonly described effect for EA2-causing mutations. On another hand, the patient bearing variant p.T501M, 
a change reported previously in EA224, presents with a phenotype that combines EA2 and HM. The functional 
analysis of this missense change revealed a gain of function of the channel, a pathogenic mechanism typical of 
HM rather than EA2. There are other reported cases where related phenotypes overlap, such as HM with progres-
sive ataxia31 or EA2 with migraine24. The third missense variant, p.P2222L, was not functionally characterized. 
Although this variation was also detected in the mother of the index case, also with episodic ataxia (Fig. 2), nei-
ther SIFT32 nor PolyPhen-233 predicted a damaging effect, whereas PhyloP34 scored it as a moderately conserved 
residue, and PhastCons35 as a highly conserved one (Table 1). The variant, rare, was not found in a set of around 
600 exomes of the CIBERER Spanish Variant Server nor among 200 healthy Spanish individuals screened by 
us, and it was found at heterozygosity in only 4 out of 6,000 subjects from the ExAC database (although this last 
figure should be taken with caution as the relevant position is covered only in 10% of the individuals, possibly 
indicating low-quality sequences). These indicators (a rare conserved variant that cosegregates with the disorder 
but has no favourable damaging effect predictors) are contradictory and thus a functional test is needed to shed 
light on the impact of the p.P2222L change.
Taking together this and other studies, no specific prevalent variants are found in EA2, which results in large 
allelic heterogeneity. However, there are some regions in the CACNA1A gene that are found to be more frequently 
mutated in EA2 patients and also in other patients presenting ataxic features (cerebellar ataxia)26. In our study, 
five out of nine variants are located in the S5-S6 extracellular loop of different domains (I, II and IV) (Fig. 1). 
Many disease-causing changes, both nonsense and missense, in EA2 seem to be preferentially located in these 
areas. Therefore, this S5-S6 linker may represent a key region that influences the proper functionality of the sub-
unit. This effect has also been seen in mouse models bearing changes in this region, which present a mild ataxia 
phenotype36. Only one variant in our study, p.T501M, present in a patient with EA2 and HM, is located in a trans-
membrane domain (DII-S1) that belongs to the voltage sensor part, affecting both activation and inactivation of 
the channel25.
Three other variants identified here are located in the C-terminal tail. The two nonsense variants p.Y1849* 
and p.R1857* are in exon 37, within the EF-hand responsible for calcium binding, so the IQ-like CaM inter-
action domain (IQ) and the Calmodulin Binding Domain (CBD)36, located donwstream, are also lost. Finally, 
although the missense variant p.P2222L is located downstream from these interaction regions (EF-hand and 
calmodulin binding domains), it may affect the conformation of the tail and disturb the interaction between the 
CACNA1A subunit and other elements that bind the C-terminal region, such as auxiliary β-subunits37, 38, leading 
to an impaired function of the channel.
Genotype-phenotype correlations were not apparent in our cohort: all pathogenic variants described in this 
study produced comparable EA2 phenotypes regardless of their molecular nature or they location in transmem-
brane or cytoplasmic tail protein domains. Of note, two patients (cases 340 and 389A) displayed the same variant 
p.R1857*; in that particular instance the clinical presentation was similar in the early age of onset and presence 
of interictal cerebellar signs.
In summary, we have identified nine potentially disease-causing variants in ten patients with episodic ataxia. 
However, there is still a significant proportion of subjects with this phenotype that bear no mutations in the 
CACNA1A gene. Although there might be some degree of missing allelic heterogeneity in CACNA1A, possi-
bly other genes are involved in the disorder in our sample, which may be uncovered by means of next gener-
ation sequencing approaches. Indeed, genes other than CACNA1A have previously been involved in episodic 
ataxia, including KCNA1 (episodic ataxia type 1, EA1)39, CACNB4 (EA4)40 and SLC1A3 (EA6)41. More recently, 
other potential EA genes have been reported, including SCN2A42, FGF1443 and SLC2A144. With the exception of 
CACNA1A and KCNA1, the rest have been found mutated in only one or a few patients, indicating that the num-
ber of genes involved in this neurologic phenotype may be high.
Methods
Patients. All 49 patients were diagnosed with episodic ataxia on clinical grounds by expert neurologists. 
Central to the diagnosis was eliciting a history of recurrent paroxysmal attacks of ataxia, vertigo, and nausea or 
vomiting typically lasting minutes to days in duration. Additional supporting criteria were (i) the presence of 
interictal ataxia and nystagmus; (ii) a history of the attacks being triggered by exercise, emotional stress, alcohol, 
caffeine, fever, or heat; (iii) reduction of attack frequency/severity by acetazolamide; (iv) absence of myokymia 
and (v) a family history consistent with autosomal dominant inheritance.
Sampling and mutation screening. Peripheral blood samples were collected from all probands and 
genomic DNA was isolated using a standard salting-out method45. All 48 exons, splice sites and branch points 
from the CACNA1A gene were sequenced. The promoter (894 bp upstream from the translation initiation codon) 
and the 3′UTR region, containing exon 48, were also screened as previously described25, 46. All variants were 
assessed by bidirectional sequencing and confirmed by restriction fragment length polymorphism (RFLP) anal-
ysis. Two hundred control individuals were screened by Sanger sequencing, and the presence of the identified 
mutations was investigated at the Exome Aggregation Consortium dataset (ExAC, http://exac.broadinstitute.org) 
and the CIBERER Spanish Variants Server (http://csvs.babelomics.org). Seven relatives from four of the fam-
ilies with identified CACNA1A mutations were also screened by Sanger sequencing and RFLP analysis. 
Variant nomenclature follows Human Genome Variation Society (HGVS) guidelines (http://www.hgvs.org/
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mutnomen/recs-DNA.html) and refers to the CACNA1A cDNA sequence NM_001127221 (protein sequence 
NP_001120693), with nucleotide c.279A corresponding to the initiation codon (ATG).
CNV analysis. Multiplex Ligation-dependent Probe Amplification (MLPA) was the first approach used for 
the CNV analysis. We used the MLPA CACNA1A kit SALSA-P279-A2 (MRC Holland, Amsterdam) that contains 
25 probes covering 24 exons of the CACNA1A gene. This test was performed according to the manufacturer’s 
instructions. Quantitative Multiplex PCR of Short fluorescent Fragments (QMPSF) was used as a complementary 
approach to cover most of the exons that were not covered by the MLPA assay. Four sets of probes targeting 16 
additional exons were designed. For five additional exons, since they were located <1 kb from the ones targeted 
by QMPSF or MLPA and no repeat sequences were present between them, deletion risk was considered as very 
low. A reference fragment from the RNF20 gene was co-amplified in each multiplex. A new set of probes was 
designed to confirm the deletion identified by MLPA in one of the patients, containing the deleted exon and the 
flanking ones.
The MLPA analysis software Coffalyser v8 was used to evaluate the possible presence of CNVs, considering 
deletion when the ratio was under 0.7 and duplication when it was over 1.3. QMPSF data were analyzed using 
the PeakScanner™ v1.0 software (Applied Biosystems), and the final ratios for each exon were expressed using 
the following formula: (height of the peak corresponding to the tested fragment for the patient/height of the peak 
corresponding to RNF20 for the patient)/(height of the peak corresponding to the tested fragment for the average 
of controls/height of the peak corresponding to RNF20 for the average of controls). We considered a deletion 
when the ratio was under 0.6 and duplication when it was over 1.4. More details about the design and analysis are 
provided in Supplementary Fig. S2. PCR conditions and sample analysis procedures are available upon request.
In order to map the breakpoint of the deletion spanning exon 35, we PCR-amplified and Sanger-sequenced 
a genomic region containing exons 34 to 36 from the carrier patient (primers and conditions available upon 
request).
Nonsense-mediated mRNA decay (NMD) assay. Only in one case biological material was available to 
perform NMD assays. Fibroblast primary cultures from a control individual and from patient 432B (bearing the 
nonsense variant p.W320*) were obtained from skin biopsies, cultured in a monolayer at 37 °C under 5% CO2 in 
T25 flasks (Greiner Bio-One, North America, Inc.) with DMEM medium (Sigma-Aldrich, Steinheim, Germany) 
containing 12% fetal bovine serum (FBS) (Gibco, Invitrogen Life Technologies, Heidelberg, Germany). After 
three weeks of maintenance, fibroblasts were tripsinized and cultured in 35mm dishes with DMEM medium con-
taining 10% FBS and 1% Penicillin-Streptomicine (Invitrogen Life Technologies, Heidelberg, Germany).
To proceed with the NMD assay, WT and mutated cells were then cultured in a six well-plate each, and three 
replicates were treated with cycloheximide, a NMD inhibitor, at 1mg/ml during 6 hours.
RNA extraction from fibroblasts and reverse transcription polymerase chain reaction (RT-PCR) were per-
formed using QIAshredder (Qiagen, Hilden, Germany) and High Capacity cDNA kit (Applied Biosystems) and 
following the manufacturer’s instructions. A segment of the CACNA1A cDNA including exon 6 was amplified 
in all samples. PCR products were sequenced and digested with AccI, enzyme that cuts the fragment bearing the 
pathogenic variant. The PCR products were electrophoresed on a 2% agarose gel, stained with EtBr and quantified 
using the ImageJ software (https://imagej.nih.gov/ij).
All methods were performed in accordance with the relevant guidelines and regulations. This study 
was approved by the local Ethics Committee, the Institutional Review Board of the University of Barcelona 
(IRB00003099), and informed consent was obtained from all adult subjects, children, and their parents according 
to the Helsinki declaration.
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